The Prediction of Serum HBP and Presepsin Levels on Acute Kidney Injury in Patients with Severe Sepsis
Objective To evaluate predictive values of serum HBP and presepsin levels on acute kidney injury in patients with severe sepsis.Methods 120 patients diagnosed with severe sepsis and treated at our hospital from September,2022 to September,2023 were selected as the research subjects.According to the relevant criteria of the Global Renal Disease Prognostic Organization Acute Kidney Injury Clinical Practice Guidelines (2012),35 patients had AKI and 85 did not.The serum HBP and presepsin expression levels between the two groups were compared,and the diagnostic efficacy of combined detection of serum HBP and presepsin for acute injury was studied.Results HBP and presepsin levels in the AKI group were significantly higher than those in the non-AKI group (P<0.05).There was no significant difference between the two groups in terms of heart rate,mechanical ventilation time,ICU stay time,systolic pressure,diastolic pressure,mean arterial pressure,APACHE Ⅱ,or SOFA scores (P>0.05).The central venous pressure,blood creatinine,blood urea nitrogen,and blood lactate levels were significantly higher in the AKI group than in the non-AKI group (P<0.05).Elevated HBP,presepsin,central venous pressure,blood creatinine,blood urea nitrogen,and blood lactate were all identified as risk factors for acute kidney injury.Combined detection of serum HBP and presepsin had a significantly higher sensitivity for predicting AKI than single-marker detection.ROC curve showed that the combined detection of serum HBP and presepsin had a significantly higher AUC value for predicting AKI than single-marker detection.According to the cutoff value analysis,the serum HBP and presepsin levels were 281.12 ng/mL and 1255.99 pg/mL,respectively,for severe sepsis patients with AKI. Conclusion The dynamic changes in serum HBP and presepsin expressions in patients with severe sepsis have significant clinical significances for predicting AKI and can serve as an important clinical standard.